Literature DB >> 7729416

Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53.

M J Allday1, A Sinclair, G Parker, D H Crawford, P J Farrell.   

Abstract

Epstein-Barr virus (EBV) efficiently converts resting human B cells into actively cycling, immortal, lymphoblastoid cell lines (LCLs). Here we show that LCLs expressing the full complement of latent viral genes are very sensitive to DNA-damaging agents such as cisplatin. The response includes a rapid accumulation of the tumour suppressor protein p53 and induction of the cellular genes mdm2 and WAF1/p21. Although the levels of Bcl2 protein and Bax mRNA appear unaltered by the activation of p53, within 24 h the majority of cells undergo apoptosis. Over-expression of wild-type p53 in an LCL also resulted in apoptosis; this was preceded by the dephosphorylation of the retinoblastoma gene product, pRb. Primary resting B cells showed no response to cisplatin and even after drug treatment, p53 remained undetectable. However, after infection with EBV, p53 gene expression was induced to a similar level to that found in mitogen-activated B cells. When the physiologically activated primary B cells were exposed to cisplatin, although p53 accumulated as in LCLs, the outcome was growth-arrest rather than gross cell death. We conclude that, in contrast to the transformation of fibroblasts by adenovirus, SV40 or HPV, when B cells become activated and immortalized by EBV they are sensitized to the p53-mediated damage response. When the resulting LCLs are treated with genotoxic agents such as cisplatin, they are unable to arrest like normal cells because they are driven to proliferate by EBV and consequently undergo apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729416      PMCID: PMC398223          DOI: 10.1002/j.1460-2075.1995.tb07124.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  56 in total

1.  Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells.

Authors:  K P Mann; D Staunton; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

2.  Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.

Authors:  Y Wang; L Szekely; I Okan; G Klein; K G Wiman
Journal:  Oncogene       Date:  1993-12       Impact factor: 9.867

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 4.  Braking the cycle.

Authors:  T Hunter
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

5.  p53 and E2F-1 cooperate to mediate apoptosis.

Authors:  X Wu; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.

Authors:  C Y Chen; J D Oliner; Q Zhan; A J Fornace; B Vogelstein; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 7.  An evolutionary perspective on apoptosis.

Authors:  D L Vaux; G Haecker; A Strasser
Journal:  Cell       Date:  1994-03-11       Impact factor: 41.582

8.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.

Authors:  S W Lowe; H E Ruley
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

9.  Bcl-2 blocks p53-dependent apoptosis.

Authors:  S K Chiou; L Rao; E White
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

10.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

View more
  32 in total

1.  Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, Zta.

Authors:  A Rodriguez; M Armstrong; D Dwyer; E Flemington
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 2.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

3.  MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.

Authors:  Eleonora Forte; Micah A Luftig
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

4.  Adenovirus type 12-induced fragility of the human RNU2 locus requires p53 function.

Authors:  Z Li; A Yu; A M Weiner
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.

Authors:  C Cayrol; E K Flemington
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

Review 7.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

8.  Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins.

Authors:  M Wade; M J Allday
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

9.  Cell cycle analysis of Epstein-Barr virus-infected cells following treatment with lytic cycle-inducing agents.

Authors:  A Rodriguez; E J Jung; E K Flemington
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Cell cycle stage-specific phosphorylation of the Epstein-Barr virus immortalization protein EBNA-LP.

Authors:  M K Kitay; D T Rowe
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.